Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide

Mallick, Supriya; Gandhi, Ajeet Kumar; Sharma, Daya Nand; Gupta, Seema; Haresh, K.P.; Rath, Goura Kishor; Julka, Pramod Kumar

doi:10.1007/s00381-015-2919-8

Cited by 10 publications

(6 citation statements)

References 12 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They showed that temozolamide is well tolerated by pediatric patients and survival data with temozolamide therapy was encouraging. The two-year progression free and overall survival rates were 44.2 and 62.9%, respectively [27].…”

Section: Discussionmentioning

confidence: 98%

Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature

et al. 2021

View full text Add to dashboard Cite

Background Gliosarcoma is a rare variant of IDH- wild type glioblastoma with both glial and mesenchymal differentiation. It accounts for approximately 2% of glioblastomas and has a poor prognosis similar to that of classic glioblastoma. It is seen mostly between 40 and 60 years of age with a mean age over 50 years. Pediatric gliosarcoma is even rarer than gliosarcoma in adults. We describe the clinicopathological features of gliosarcoma in patients under 20 years of age and determine whether there are significant differences from gliosarcoma in adults. We also present detailed review of published literature on pediatric gliosarcoma. Methods Slides of gliosarcomas in patients under 20 years of age were reviewed. Clinicopathological features were noted in detail and follow up was obtained. Results Eleven cases of gliosarcoma were reported in patients under 20 years of age. Ages ranged from three to 19 years (mean age 13 years). Frontal, parietal and temporal lobes were the commonest locations. Mean and median tumor size was six and five cm respectively. All 11 cases demonstrated the classic biphasic pattern. In 10 cases, glial component was astrocytic and was highlighted on GFAP. Sarcomatous component in most cases resembled fibrosarcoma and was high grade in 72.7%. Glial areas were reticulin poor while sarcomatous areas were reticulin rich. In over 45% cases, bizarre tumor giant cells were seen in the sarcomatous areas. In 1 case, sarcomatous areas showed extensive bone and cartilage formation. Other histologic features included hyalinized blood vessels, hemorrhage, infarction, gemistocytic cells, rhabdoid cells etc. Follow up was available in nine patients, five received chemoradiation post resection while three received radiotherapy only. Prognosis was dismal and eight patients died within one to 14 months following resection. Conclusions Gliosarcomas in patients under 20 comprised 13% of all gliosarcomas reported during the study period. Frequency and mean age were higher compared to other published reports. Pathological features were similar to those described in literature. Clinicopathological features and prognosis of pediatric gliosarcomas were similar to adult gliosarcomas.

show abstract

Section: Discussionmentioning

confidence: 98%

Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature

et al. 2021

View full text Add to dashboard Cite

show abstract

“…During childhood, pineal tumors are more common, corresponding to 3%-11% of all pediatric central nervous system tumors. However, only 25 cases of pediatric nonpineal gliosarcoma had been reported, none of them in pineal topography [4] , [5] .…”

Section: Discussionmentioning

confidence: 99%

“…A literature review by Mallick et al. found a total of 25 reported cases of nonpineal pediatric gliosarcoma [4] .…”

Section: Introductionmentioning

confidence: 99%

Pineal gliosarcoma in a 5-year-old girl

Granados

Ospina

Paredes

2018

Radiology Case Reports

View full text Add to dashboard Cite

The purpose of this paper is to report a rare case of a pediatric pineal gliosarcoma. Gliomas on the pineal region are uncommon, representing 0.4%-1% of all brain tumors. Furthermore, pediatric gliosarcomas are a very rare entity. We present a case of a 5-year-old girl, with a history of headache, vomiting, diplopia, and gait disturbances. A pineal tumor was found with pathology results consistent with a gliosarcoma. A total of 25 cases of pediatric gliosarcomas have been reported, none of them in pineal topography. Only 3 gliosarcomas were found in the pineal region, but these were found in adults. To our knowledge, this is the first pediatric pineal gliosarcoma reported in the literature.

show abstract

“…2,3 Because of the rarity of pediatric gliosarcomas, these tumors are poorly characterized clinically and molecularly. 1,4 Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome defined by mutation of the NF1 gene, a well-known tumor suppressor of the RAS oncogene. Individuals with NF1 are known to be at a higher risk of developing gliomas including high-grade tumors 5 such as GBM; however, published reports of gliosarcoma in NF1 patients are limited to adult cases with only sparse molecular data.…”

mentioning

confidence: 99%

“…Only about 2% of childhood GBMs are gliosarcomas1 accounting for only 2 cases annually in the United States 2,3. Because of the rarity of pediatric gliosarcomas, these tumors are poorly characterized clinically and molecularly 1,4. Neurofibromatosis type 1 (NF1) is a neurocutaneous syndrome defined by mutation of the NF1 gene, a well-known tumor suppressor of the RAS oncogene.…”

mentioning

confidence: 99%

Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients

Graham

Bell

Webb

et al. 2020

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Gliosarcoma is rare among pediatric patients and among individuals with Neurofibromatosis Type 1 (NF1). Here we compare 2 pediatric gliosarcoma patients, one of whom has NF1. We performed whole-exome sequencing, methylation, and copy number analysis on tumor and blood for both patients. Whole-exome sequencing showed higher mutational burden in the tumor of the patient without NF1. Copy number analysis showed differences in chromosomal losses/gains between the tumors. Neither tumor showed O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. The NF1 patient survived without progression while the other expired. This is the first reported case of gliosarcoma in a child with NF1.

show abstract

Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide

Abstract: Adjuvant radiotherapy and temozolomide is well tolerated and show an encouraging survival in pPGS.

Cited by 10 publications

References 12 publications

Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature

Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature

Pineal gliosarcoma in a 5-year-old girl

Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients

Contact Info

Product

Resources

About